Thanks for posting RVX_Anonymous. With regards to BET inhibitors, such as ZEN-3694, I don't think this changes anything. Abiraterone, which was the subject of this recent study, as well as Enzalutamide were already second line treatments for patients whose prostate cancer had progressed after androgen deprivation therapy (ADT) or castration therapy. These new results suggest that it may be a good idea to start the abiraterone treatment as part of the first line therapy instead of waiting until the cancer has clearly progressed past ADT or castration therapy alone. I think similar studies are being done for enzalutamide, but I'm not sure. Abiraterone and/or Enzalutatide resistance will still occur in a subset of patients, leading to hormone/castration resistant prostate cancers. This is where the BET inhibitor opportunity resides.

BearDownAZ